title: Extramedullary orbital granulocytic sarcoma without bone marrow involvement: a report of two cases.
abstract: The authors present herein 2 extramedullary orbital granulocytic sarcoma (GS) cases without bone marrow involvement in view of their rarity and also to reevaluate the treatment approach in this disease. Seven days of high-dose methyl prednisolone (HDMP) treatment (3 days 30 mg/kg/day and 4 days 20 mg/kg/day) was administered initially, and subsequently Acute Myeloid Leukaemia-Berlin Frankfurt Münster (AML-BFM) 2004 treatment protocol was continued for 2 cases. Eye findings of the cases resolved considerably with HDMP treatment. They have still been under systemic chemotherapy without any complication for 1 year. Thus, early diagnosis and AML-targeted intensive chemotherapy improve the prognosis of GS even if there is no bone marrow involvement.
authors.affiliation: Department of Pediatric Hematology, Ankara Children's Hematology and Oncology Hospital, Ankara, Turkey.
authors.forename: Pamir
authors.initials: P
authors.lastname: Isik
authors.forename: Betul
authors.initials: B
authors.lastname: Tavil
authors.forename: Bahattin
authors.initials: B
authors.lastname: Tunç
authors.forename: Nese
authors.initials: N
authors.lastname: Yarali
authors.forename: Ahmet
authors.initials: A
authors.lastname: Demir
authors.forename: Mualla
authors.initials: M
authors.lastname: Cetin
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000175:diagnosis / Q000188:drug therapy*; D008279:Magnetic Resonance Imaging; D011239:Prednisolone / Q000008:administration & dosage / Q000627:therapeutic use*; D011379:Prognosis; D023981:Sarcoma, Myeloid / Q000175:diagnosis / Q000188:drug therapy*
chemical_list: D011239:Prednisolone